At Day 60, patients receivingtestosterone gel were maintained at the same dose, or were titrated up or downwithin their treatment group, based on 24-hour averaged serum testosteroneconcentration levels obtained on Day 30. When dosed to similar serum testosterone targets, topical preparations provide symptom relief and biochemical normalization comparable to injectable forms, but with steadier hormone levels and no injection discomfort, at the cost of daily application and a risk of unintentional transfer to close contacts. Subjects could be counted in both testosteronegel treatment groups if they received both 50 mg and 100 mg at different pointsin the study and experienced an adverse reaction at both dose levels. The recommended starting dose of Vogelxo is 50 mg oftestosterone (one tube, one packet, or 4 pump actuations) applied topicallyonce daily at approximately the same time each day to clean, dry intact skin ofthe shoulders and/or upper arms. The recommended starting dose of Vogelxo is 50 mg of testosterone (one tube, one packet, or 4 pump actuations) applied topically once daily at approximately the same time each day to clean, dry intact skin of the shoulders and/or upper arms. Adverse effects of testosterone supplementation may include increased cardiovascular events (including strokes and heart attacks) and deaths based on three peer-reviewed studies involving men taking testosterone replacement. Serum concentrations oftestosterone were monitored in the female subjects for 24 hours after thetransfer procedure. About 6% of a dose is excretedin the feces, mostly in the unconjugated form. There is considerable variationin the half-life of testosterone concentration as reported in the literature,ranging from 10 to 100 minutes. Some female athletes may have naturally higher levels of testosterone than others, and may be asked to consent to sex verification and either surgery or drugs to decrease testosterone levels. However, it has been reported that AndroGel, a transdermal gel formulation of testosterone, has become the most popular form of testosterone in androgen replacement therapy for hypogonadism in the United States. There are approved testosterone products for women in Australia, where it is considered a drug of dependence, medicines that are subject to misuse and trafficking, and some European countries. As of November 2016update, testosterone is available in Canada in the form of topical gels (AndroGel, Testim), topical solutions (Axiron), transdermal patches (Androderm), and intranasal gels (Natesto). The pharmacokinetics of testosterone, including its bioavailability, circulating testosterone levels, metabolism, biological half-life, and other parameters, differ by route of administration. These metabolites, along with estradiol, may be involved in a number of the effects of testosterone in the brain, including its antidepressant, anxiolytic, stress-relieving, rewarding, and pro-sexual effects. Estrogens can reduce the effects of testosterone by increasing the hepatic production and in turn circulating levels of sex hormone-binding globulin (SHBG), a carrier protein that binds to and occupies androgens like testosterone and DHT, and thereby reducing free concentrations of these androgens. As only a very small fraction of testosterone is converted into estradiol, this does not affect testosterone levels, but it can prevent estrogenic side effects like gynecomastia that can occur when testosterone is administered at relatively high dosages. Of 192 hypogonadal men who were appropriately titratedwith testosterone gel and who had sufficient data for analysis, 74% achieved anaverage serum testosterone level within the normal range (300 to 1,000 ng/dL)on treatment Day 90. During the first 60 days, patientswere evenly randomized to testosterone gel 50 mg, testosterone gel 100 mg,placebo gel, or testosterone transdermal system. The study wasdouble-blind for the doses of testosterone gel and placebo, but open label forthe nonscrotal testosterone transdermal system. Testosterone gel was evaluated in a randomizedmulticenter, multi-dose, active and placebo controlled 90-day study in 406adult males with morning testosterone levels ≤ 300 ng/dL. The effect of showering (with mild soap) at 1, 2 and 6hours post application of testosterone gel 100 mg was evaluated in a clinicaltrial in 12 men. Unlike testosterone, AAS that are 17α-alkylated, like metandienone and stanozolol, are orally active. This occurs in many tissues, especially adipose tissue, the liver, and the brain, but primarily in adipose tissue. In addition to DHT, testosterone is converted at a rate of approximately 0.3% into the estrogen estradiol via aromatase. Testosterone gel should be promptly discontinued until thecause of virilization has been identified. Changes in insulin sensitivity or glycemic control mayoccur in patients treated with androgens. Because the reactionsare reported voluntarily from a population of uncertain size, it is not alwayspossible to reliably estimate their frequency or establish a causalrelationship to drug exposure. The patient should avoid swimming or showering or washingthe administration site for a minimum of 2 hours after application seeCLINICAL PHARMACOLOGY. In order to prevent transfer to another person, clothingshould be worn to cover the application sites. Hands should be washed thoroughly with soap and waterafter Vogelxo has been applied. Table 2 has specific dosing guidelines for whenthe metered pump is used.
